Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Recurrent Uterine Leiomyosarcoma
NCT00025220Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2001
- Primary completion
- Apr 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in uterine leiomyosarcoma (uLMS), sponsored by National Cancer Institute. Primary endpoints: Progression-free survival at 6 months and Frequency and severity of adverse effects up to 7 years. Started Sep 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT00025220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025220.